In the News

Biosimilar Development
How To Prepare Your Biosimilar Company For Interchangeability

Anna Rose Welch
Sep 21, 2016

At the inaugural GPhA Biosimilars Council’s Leading on Biosimilars conference, I was made privy to the industry’s many opinions and questions about interchangeability. While biosimilar makers are anxiously awaiting interchangeability guidance from the FDA, there did not seem to be a united or clear opinion about whether interchangeability will be a beneficial strategy for biosimilar makers. However, in an interview, Pankaj Mohan, CEO of pure-play biosimilar company Oncobiologics, offered a very straight-forward and optimistic perspective. “Interchangeability will be a game changer for biosimilars,” he said.

Please click on the link to read the rest of the story …

< back